Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helen X Chen

Showing results (41-50 of 85) with videos related to

Pageof 9
Sort By:
American Heart Journal|February 7, 2012
Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitorsRichard M Steingart, George L Bakris, Helen X Chen, et al.
Cancer|April 21, 2021
A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: High-grade neuroendocrine neoplasm cohortSandip Pravin Patel, Edward Mayerson, Young Kwang Chae, et al.
Journal of the National Cancer Institute|March 31, 2010
Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitorsMichael L Maitland, George L Bakris, Henry R Black, et al.
Journal of Hepatology|September 19, 2013
A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinomaGhassan K Abou-Alfa, Marinela Capanu, Eileen M O'Reilly, et al.
Cancer|May 11, 2016
Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508)Chandra P Belani, Suzanne E Dahlberg, Charles M Rudin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 24, 2009
A phase I study of sunitinib plus bevacizumab in advanced solid tumorsBrian I Rini, Jorge A Garcia, Matthew M Cooney, et al.
Journal for Immunotherapy of Cancer|September 29, 2024
Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the desmoid tumorsYoung Kwang Chae, Megan Othus, Sandip Patel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2011
Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology GroupSuman Malempati, Brenda Weigel, Ashish M Ingle, et al.
Therapeutic Advances in Medical Oncology|November 25, 2024
Phase II trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors SWOG/NCI experience: invasive mucinous or non-mucinous lepidic adenocarcinoma of the lung (formerly bronchioloalveolar carcinoma)Young Kwang Chae, Megan Othus, Sandip Pravin Patel, et al.
Investigational New Drugs|April 10, 2013
Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patientsDouglas A Rubinson, Howard S Hochster, David P Ryan, et al.
Pageof 9

Showing results (41-50 of 85) with videos related to

Sort By:
Pageof 9
American Heart Journal|February 7, 2012
Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitorsRichard M Steingart, George L Bakris, Helen X Chen, et al.
Cancer|April 21, 2021
A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: High-grade neuroendocrine neoplasm cohortSandip Pravin Patel, Edward Mayerson, Young Kwang Chae, et al.
Journal of the National Cancer Institute|March 31, 2010
Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitorsMichael L Maitland, George L Bakris, Henry R Black, et al.
Journal of Hepatology|September 19, 2013
A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinomaGhassan K Abou-Alfa, Marinela Capanu, Eileen M O'Reilly, et al.
Cancer|May 11, 2016
Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508)Chandra P Belani, Suzanne E Dahlberg, Charles M Rudin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 24, 2009
A phase I study of sunitinib plus bevacizumab in advanced solid tumorsBrian I Rini, Jorge A Garcia, Matthew M Cooney, et al.
Journal for Immunotherapy of Cancer|September 29, 2024
Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the desmoid tumorsYoung Kwang Chae, Megan Othus, Sandip Patel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2011
Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology GroupSuman Malempati, Brenda Weigel, Ashish M Ingle, et al.
Therapeutic Advances in Medical Oncology|November 25, 2024
Phase II trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors SWOG/NCI experience: invasive mucinous or non-mucinous lepidic adenocarcinoma of the lung (formerly bronchioloalveolar carcinoma)Young Kwang Chae, Megan Othus, Sandip Pravin Patel, et al.
Investigational New Drugs|April 10, 2013
Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patientsDouglas A Rubinson, Howard S Hochster, David P Ryan, et al.
Pageof 9